pt2385
Small moleculeexperimental
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2014 (NCT02293980)
Timeline
Indications
Mechanism of action
- Hypoxia-inducible factor 1-alphaINHIBITOR
HIF1A inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- pt2385
- pt2385
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04989959 | Phase 1 | Aug 18, 2021 | The University of Texas, Dallas |
| NCT03216499 | Phase 2 | Aug 15, 2017 | Johns Hopkins University, Wake Forest University |
| NCT03108066 | Phase 2 | Apr 1, 2017 | National Institutes of Health (NIH), Peloton Therapeutics, Inc. |
| NCT02553356 | Phase 1 | Sep 1, 2015 | Peloton Therapeutics, Inc. |
| NCT02293980 | Phase 1 | Nov 1, 2014 | Peloton Therapeutics, Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Peloton Therapeutics, Inc. | For profit | 3 | 3 | 2 | 2014 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2017 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Wake Forest University | Academic/Hospital | 1 | 0 | 1 | 2017 |
5 organizations
Page 1 / 1